Latest Breaking News On - Pancreatic ductal - Page 1 : vimarsana.com

BOLD-100 and ATR Inhibitors as a New Avenue for PDAC Targeting at AACR 2024

/PRNewswire/ Bold Therapeutics, a clinical-stage biopharmaceutical company at the forefront of developing innovative metallotherapeutics, has announced that.

San-diego
California
United-states
South-korea
Vancouver
British-columbia
Canada
Seoul
Soult-ukpyolsi
E-russell-mcallister
Jim-pankovich
Clinical-development-at-bold-therapeutics

Oncology Drug Approval Decisions Expected in February 2024

The US Food and Drug Administration is expected to make decisions about 2 oncology drugs next month.

Drug-administration
Liposome-injection
Pancreatic-ductal
Drug-user-fee-act

Theriva Biologics, Inc.: Theriva Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results

Theriva Biologics, Inc.: Theriva Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United-states
United-kingdom
Spain
Madrid
American
Stevena-shallcross
Chris-calabrese
Institut-catala
Theriva-biologics
Ramon-alemany
Lifesci-advisors
Biomedical-research-institute-of-bellvitge

Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results

Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states
Madrid
Spain
United-kingdom
American
Chris-calabrese
Institut-catala
Stevena-shallcross
Ramon-alemany
Theriva-biologics
Company-annual-report-on-form
James-university-hospital

Pancreatic Ductal Adenocarcinoma Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Key Companies - Novartis Pharmaceuticals, Jiangsu Alphamab Biopharmaceuticals, General Oncology, Inc., ZielBio, Lisata Therapeutics, Inc., Cardiff Oncology |

Pancreatic Ductal Adenocarcinoma Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Key Companies - Novartis Pharmaceuticals, Jiangsu Alphamab Biopharmaceuticals, General Oncology, Inc., ZielBio, Lisata Therapeutics, Inc., Cardiff Oncology |
medgadget.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medgadget.com Daily Mail and Mail on Sunday newspapers.

France
Germany
Atroas
Galicia
Spain
Japan
China
Italy
United-states
United-kingdom
Nevada
America